Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial

作者：Hendriksz Christian J^*; Giugliani Roberto; Harmatz Paul; Mengel Eugen; Guffon Nathalie; Valayannopoulos Vassili; Parini Rossella; Hughes Derralynn; Pastores Gregory M; Lau Heather A; Al Sayed Moeenaldeen D; Raiman Julian; Yang Ke; Mealiffe Matthew; Haller Christine

来源：Molecular Genetics and Metabolism, 2015, 114(2): 178-185.

DOI：10.1016/j.ymgme.2014.08.012

• Morquio A syndrome
• Mucopolysaccharidosis IVA
• Lysosomal storage disorder
• Randomized controlled trial
• Elosulfase alfa
• Enzyme replacement therapy

Objective: To report and discuss the multi-domain impact of elosulfase alfa, with focus on tertiary and composite endpoints, in the 24-week, randomized, double-blind, placebo-controlled phase 3 trial in patients with Morquio A syndrome (mucopolysaccharidosis IVA).
Methods: Patients with Morquio A syndrome >= 5 aged years were randomized 1:1:1 to elosulfase alfa 2.0 mg/kg/week (qw; N = 58), elosulfase alfa 2.0 mg/kg/every other week (qow; N = 59), or placebo (N = 59) for 24 weeks. Primary and secondary efficacy measures were 6-minute walk test (6MWT; primary), 3-minute stair climb test (3-MSCT) and urinary keratan sulfate (KS). Safety was also evaluated. Tertiary efficacy measures included respiratory function measures, activities of daily living (MPS Health Assessment Questionnaire [MPS-HAQ]), anthropometric, echocardiographic and radiographic measures, hearing and corneal clouding assessment. In order to fully characterize treatment impact in this heterogeneous disorder, the effect of elosulfase alfa on composite efficacy measures was evaluated as well.
Results: The study was not designed to have sufficient power for any of the tertiary outcomes. For most tertiary endpoints, subjects treated with the weekly dose of elosulfase alfa improved more than those receiving placebo. The largest treatment effects were seen in maximal voluntary ventilation (MVV), MPS-HAQ height, and growth rate. The qow group appeared similar to placebo. The analysis of a pre-specified composite endpoint (combining changes from baseline in 6MWT, 3MSCT and MW z-scores equally weighted) showed a modest positive impact of elosulfase alfa qw versus placebo group (P = 0.053). As a pre-specified supportive analysis, the O'Brien Rank Sum composite endpoint (changes from baseline in 6MWT, 3MSC, and MW), analysis also showed that the qw group performed better than the placebo group (P = 0.011). In post-hoc analyses, combinations of other endpoints were also explored using the O'Brien Rank Sum test and showed statistically significant differences between elosulfase alfa qw and placebo favoring elosulfase alfa qw. Differences between elosulfase alfa qow and placebo were not statistically significant. Positive changes were observed in most tertiary variables, demonstrating the efficacy of weekly treatment with elosulfase alfa.
Conclusions: Treatment with weekly elosulfase alfa led to improvements across most efficacy measures, resulting in clinically meaningful benefits in a heterogeneous study population.

• 出版日期2015-2